TITLE

Branded Drug Manufacturers Look to Hone Competitive Edge

PUB. DATE
February 2011
SOURCE
Chain Drug Review;2/28/2011, Vol. 33 Issue 4, p55
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the drastic measures taken by major pharmaceutical firms such as Pfizer Inc., Merck & Co. and Novartis AG to compete which include cutting back on research and development to withdrawing long-term profit predictions and laying-off researchers in the U.S.
ACCESSION #
59994633

 

Related Articles

  • High-growth firms in changing competitive environments: the US pharmaceutical industry (1963 to 2002). Mazzucato, Mariana; Parris, Stuart // Small Business Economics;Jan2015, Vol. 44 Issue 1, p145 

    Firms across sectors and regions are highly skewed in their ability to engage with innovation and even more skewed in their ability to translate investments in innovation into higher growth. Recent attention has been placed on the importance of 'high-growth firms' (HGF) for innovation policy....

  • R&D Costs Continue to Rise for Pharma.  // Pharmaceutical Representative;Feb2011, Vol. 41 Issue 2, p8 

    The article reports on the annual assessment issued by the Tufts Center for Drug Development revealing an increase in cost of research and development (R&D) in pharmaceutical industry in the U.S.

  • Embarking on the New World of Personalized Medicine. Lee, Albert S.; Malik, Ash; Mynhier, Mark A. // Pharmaceutical Technology;Aug2011, Vol. 35 Issue 8, p34 

    The article discusses the shift to personalized medicine market by pharmaceutical companies in the U.S. in 2011. It mentions that the move is triggered by the changing realities in the industry including competition from generic drugs, stricter regulations, and patent issues. It also notes the...

  • Industry Developments.  // U.S. Pharma & Healthcare Report;Q2 2012, Issue 2, p31 

    The article discusses developments in the U.S. pharmaceutical industry. According to the Burden of Disease Database (BoDD), the epidemiological profile of the U.S. showed that as of 2008, 51% of the 37.76 million disability-adjusted life years (DALYs) lost to injuries and disease were due to...

  • Big Pharma: Capitalism Out of Control. Nader, Ralph // Progressive Populist;1/1/2015, Vol. 21 Issue 1, p19 

    The author reflects on the apparently ignored aspects of the drug industry's research and development (R&D) including the tax credits and taxpayer funded R&D drug companies enjoy, the absence of price controls, and how much is focused on products that match, rather than improve, health results.

  • UNITED STATES PHARMACEUTICALS.  // Acquisdata Industry SnapShot: United States - Pharmaceuticals;11/18/2015, Issue 3722, preceding p1 

    An industry report of the pharmaceuticals industry in the U.S. is presented from publisher Acquisdata Pty Ltd., with topics including media releases of leading pharmaceutical companies, industry research developments as of November 18, 2015, and profiles of leading pharmaceutical companies.

  • ASYMMETRIC LEARNING CAPABILITIES AND STOCK MARKET RETURNS. HAIBIN YANG; YANFENG ZHENG; ZAHEER, AKBAR // Academy of Management Journal;Apr2015, Vol. 58 Issue 2, p356 

    Drawing on the alliance learning literature, we propose that a firm's relative capability to learn partner-specific know-how holds the key to understanding the learning race phenomenon and its performance consequences. Specifically, we argue that a firm with higher specific learning capability...

  • The Changing Face of Global Biopharm.  // R&D Magazine;Dec2008, Vol. 50 Issue 7, p54 

    The article looks at the effect on research and development (R&D) of the changes in the biotechnology and pharmaceutical (biopharm) industry. The U.S. biopharm sales revenue for the top 50 companies in 2007 rose 3.8% from 2006. Up to 2005, annual R&D investments for biopharm companies are said...

  • 5 Industry Predictions for 2011. Chatterjee, Bikash // Pharmaceutical Processing;Jan2011, Vol. 26 Issue 1, p18 

    The article discusses trends which are expected to continue or emerge in the U.S. pharmaceutical processing industry in 2011. According to industry analysts, the drug delivery market division will have a significant growth in 2011. It says that the pressure on the industry and the U.S. Food and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics